π¬ Govt cracks down on GLP-1 drug marketing
The Central government has ordered tighter surveillance on the promotion of GLP-1 weight-loss drugs due to surrogate advertising worries. This directive was issued following concerns about misleading awareness campaigns across states and UTs. The CDSCO had already issued advisories on March 10, 2026, and March 27, 2026, to relevant parties. These rules ensure drugs are used only for approved indications under specialist prescriptions to minimize risks. Regulators must now monitor all advertising platforms to stop non-compliant promotion. π